Infliximab
Infliximab is a biologic medication that works by blocking tumor necrosis factor alpha (TNFα), a protein that causes inflammation in the body. It is used to treat autoimmune conditions including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Infliximab is a TNFα inhibitor biologic used to treat various autoimmune inflammatory conditions.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L04AB02
- RxNorm
- 191831
- Generic
- Infliximab
- Class
- atc-l04
- Brands
- Inflectra, Renflexis, Remicade, Avsola, Zymfentra
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks
- Maximum
- consult physician
- Frequency
- every 8 weeks (maintenance)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks
- Maximum
- consult physician
- Frequency
- every 8 weeks (maintenance)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks
- Maximum
- consult physician
- Frequency
- every 8 weeks (maintenance)
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh risks; discontinue if pregnancy occurs unless clinically needed
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesterconsider discontinuation near term
may cross placenta; consider risks vs benefits; discuss with maternal-fetal medicine
fetal growth monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
compatible with breastfeeding; minimal transfer to breast milk
routine infant monitoring
pediatric_age
pediatric crohnweight-based dosing
approved for pediatric Crohn disease and ulcerative colitis; use under specialist supervision
growth and development monitoring
Use with caution and monitor for adverse effects.
geriatric
elderlyno specific adjustment
use with caution; increased infection risk; consider comorbidities
regular infection surveillance
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno dose adjustment required
no significant change in pharmacokinetics; use standard dosing
standard renal function monitoring
renal_impairment
severeuse with caution
limited data in severe renal impairment; monitor closely
frequent renal function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateuse with caution
limited data; monitor liver function tests
regular liver function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
severenot recommended
avoid use in severe hepatic impairment due to limited data
comprehensive liver function monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
FDA approval year
First FDA approval for Remicade brand
Drug class
Biologic response modifier classification
Common uses
FDA-approved therapeutic indications
Administration route
Method of drug delivery
Treats autoimmune inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
A monoclonal antibody that binds with high affinity to TNFα, neutralizing its biological activity and preventing it from binding to cell surface receptors, thereby reducing inflammation.
Administered by intravenous infusion, typically every 6-8 weeks. Increases risk of serious infections and infusion reactions. Requires screening for tuberculosis and hepatitis B before starting treatment. May increase risk of certain cancers and heart failure. Should not be used with other biologic immunosuppressants.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy